


(nonlethal temporary incapacitation formulation and novel solvent system)

RN 7360-38-5 HCAPLUS

CN Hexanoic acid, 2-ethyl-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L58 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:501816 HCAPLUS

DOCUMENT NUMBER: 133:109988

TITLE: Transdermal antipruritic preparations with improved bioavailability

INVENTOR(S): Ohara, Kunio; Tanaka, Nobuyuki

PATENT ASSIGNEE(S): Health Science Center Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000204046	A2	20000725	JP 1999-4433	19990111
JP 3022541	B1	20000321		

PRIORITY APPLN. INFO.: JP 1999-4433 19990111

AB The prepsns. are obtained by mixing antipruritic agents and bases containing fatty acid polyalc. esters, oily substances, lower alcs., and H₂O. The prepsns. are not sticky or slimy. An aqueous liquid containing nonylic acid vanillylamide, sucrose palmitate, sucrose stearate, glyceryl tri(2-ethylhexanoate), glycerin, EtOH, and hinokitiol showed long-lasting antipruritic effect in humans without causing adverse effects.

IT 2444-46-4, Nonylic acid vanillylamide
7360-38-5, Glyceryl tri(2-ethylhexanoate)

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal antipruritic prepsns. with improved bioavailability)

RN 2444-46-4 HCAPLUS

CN Nonanamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

